Phathom Pharmaceuticals, Inc.
PHAT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001783183
No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Phathom Pharmaceuticals, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 133 | 3 | 144 | +14 |
| Shares | 72.6M | 852.1K | 66.7M | −5.11M (−7.1%) |
| Value | $1.31B | $14.9M | $541.2M | −$756.6M (−58.3%) |
3 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (36)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (22)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Portolan Capital Management, LLC | 1,699,918 | $30.7M |
| OrbiMed Advisors LLC | 1,449,073 | $26.2M |
| Federated Hermes, Inc. | 1,403,638 | $25.4M |
| Saturn V Capital Management LLC | 874,590 | $15.8M |
| Kennedy Capital Management, Inc. | 728,490 | $13.2M |
| Point72 Asset Management, L.P. | 439,816 | $7.95M |
| EAM Investors, LLC | 216,448 | $3.91M |
| Schonfeld Strategic Advisors LLC | 208,640 | $3.77M |
| D. E. Shaw & Co., Inc. | 143,707 | $2.60M |
| Moore Capital Management, LP | 130,000 | $2.35M |
| ExodusPoint Capital Management, LP | 69,282 | $1.25M |
| Balyasny Asset Management LLC | 65,659 | $1.19M |
| SEI Investments Co | 33,898 | $612.9K |
| MML Investors Services, LLC | 33,860 | $612.0K |
| Group One Trading, L.P. | 15,130 | $273.6K |
| Cowen and Company, LLC | 15,000 | $271.2K |
| SG Americas Securities, LLC | 13,483 | $244.0K |
| LVW Advisors, LLC | 13,440 | $243.0K |
| Davenport & Co LLC | 10,000 | $180.8K |
| Russell Investments Group, Ltd. | 36 | $651 |
| Capital Performance Advisors LLP | 29 | $524 |
| SRS Capital Advisors, Inc. | 17 | $308 |
Not filed for Q4 2024 yet (3)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Eagle Asset Management Inc | 455,196 | $7.67M |
| Ghost Tree Capital, LLC | 375,000 | $6.78M |
| Chartwell Investment Partners, LLC | 21,904 | $396.0K |